# US 2024/0254460 A1 · High temperature resistant reverse transcriptase mutants and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254460 A1
- Document ID: US20240254460A1
- Status: Published application
- Kind: A1
- Application number: 17/254,376
- Filed: 2020-11-13
- Published: 2024-08-01
- Earliest claimed: 2019-11-13
- Assignees: Daan Gene Co., Ltd.
- Applicants: Daan Gene Co., Ltd.
- Inventors: Xiwen JIANG; Aishan LIU; Zhouquan WANG; Sangsang ZHENG; Jiguang ZHAO; Xianlan LIAN; Xiaocheng XIE; Xuelan LU; Wei ZHANG; Haojian XU; Zhikeng FANG; Zhijian WU
- Web page: https://patentgrep.com/patent/US20240254460A1

## CPC

- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 15/1096: {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides a high temperature resistant reverse transcriptase mutant and its use. In particular, the present invention constructs a reverse transcriptase (M-MLV) mutant library, and the mutants with improved thermostability and higher amplification efficiency are finally screened out by stepwise screening. Under high temperature conditions, the reverse transcription efficiency of the reverse transcriptase mutant of the present invention is greatly improved compared to the wild type.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A reverse transcriptase mutant, wherein the reverse transcriptase mutant is mutated at at least one sites selected from the group consisting of: the amino acid residue at position 446, the amino acid residue at position 313, the amino acid residue at position 583, the amino acid residue at position 607, and the amino acid residue at position 221, wherein the amino acid residues are numbered according to SEQ ID NO: 1.

### Claim 15 (depends on 14)

The reverse transcriptase mutant according to claim 14, wherein in the reverse transcriptase mutant, the amino acid residue at position 446 is mutated to Cys; and/or
in the reverse transcriptase mutant, the amino acid residue at position 313 is mutated to His or Gln; and/or
in the reverse transcriptase mutant, the amino acid residue at position 583 is mutated to Asn; and/or
in the reverse transcriptase mutant, the amino acid residue at position 607 is mutated to Lys; and/or
in the reverse transcriptase mutant, the amino acid residue at position 221 is mutated to Arg.

### Claim 16 (depends on 14)

The reverse transcriptase mutant according to claim 14, wherein the reverse transcriptase mutant has a mutation at the amino acid residue at position 583 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1; or,
the reverse transcriptase mutant has a mutation at the amino acid residue at position 313 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1; or,
the reverse transcriptase mutant has a mutation at the amino acid residue at position 221 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1; or,
the reverse transcriptase mutant has a mutation at the amino acid residue at position 607 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1; or,
the reverse transcriptase mutant has a mutation at the amino acid residue at position 446 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1.

### Claim 17 (depends on 16)

The reverse transcriptase mutant according to claim 16, wherein the reverse transcriptase mutant has a mutation at the amino acid residue at position 583 corresponding to the amino acid sequence of wild-type murine leukemia virus reverse transcriptase (M-MLV), wherein the amino acid residue is numbered according to SEQ ID NO: 1, and wherein the amino acid residue at position 583 is mutated to Asn.

### Claim 18 (depends on 14)

The reverse transcriptase mutant according to claim 14, wherein the amino acid sequence of the reverse transcriptase mutant has at least about 80% homology; more preferably, at least about 90% homology; most preferably, at least about 95% homology; for example, at least about 96%, 97%, 98%, 99% homology with SEQ ID NO: 1.

### Claim 19 (depends on 14)

The reverse transcriptase mutant according to claim 14, wherein the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 313; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 221; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 446; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 221; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 446; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 607; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 221; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 607; or
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 446.

### Claim 20 (depends on 19)

The reverse transcriptase mutant according to claim 19, wherein the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 313; and, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 313 is mutated to His or Gln; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 221; and, the amino acid residue at position 313 is mutated to Gln, and the amino acid residue at position 221 is mutated to Arg; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 446; and, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 446 is mutated to Cys; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 583 and 221; and, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 221 is mutated to Arg; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 446; and, the amino acid residue at position 313 is mutated to Gln, and the amino acid residue at position 446 is mutated to Cys; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313 and 607; and, the amino acid residue at position 313 is mutated to Gln, and the amino acid residue at position 607 is mutated to Lys; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 221; and, the amino acid residue at position 313 is mutated to Gln, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 221 is mutated to Arg; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 607; and, the amino acid residue at position 313 is mutated to Gln, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 607 is mutated to Lys; or,
the reverse transcriptase mutant has mutations at the amino acid residues of positions 313, 583 and 446; and, the amino acid residue at position 313 is mutated to Gln, the amino acid residue at position 583 is mutated to Asn, and the amino acid residue at position 446 is mutated to Cys.

### Claim 21 (depends on 14)

The reverse transcriptase mutant according to claim 14, wherein the reverse transcription efficiency of the reverse transcriptase mutant at a high temperature (58° C.) is increased by more than 10 times compared to the wild type.

### Claim 22 (depends on 14)

A kit, wherein the kit comprises the reverse transcriptase mutant according to claim 14.

### Claim 23 (depends on 22)

The kit according to claim 22, wherein the kit further comprises one or more components selected from the group consisting of:
dNTPs, buffer, primers, probe, and pure water.

### Claim 24 (depends on 14)

Use of the reverse transcriptase mutant according to claim 14 in the preparation of a reverse transcription detection reagent or reverse transcription kit.

### Claim 25 (depends on 14)

A RNA reverse transcription method, wherein the method comprises steps of:
(1) Providing a RNA-containing sample; and
(2) Performing reverse transcription reaction,
the reverse transcriptase mutant according to claim 14 is used to perform the reverse transcription reaction on the RNA-containing sample provided in step (1).
